Adamis Pharmaceuticals Stock Forecast, Price & News

Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

Is Adamis Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Adamis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View analyst ratings for Adamis Pharmaceuticals or view top-rated stocks.

How has Adamis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Adamis Pharmaceuticals' stock was trading at $0.4029 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMP shares have increased by 86.2% and is now trading at $0.75.
View which stocks have been most impacted by COVID-19.

Are investors shorting Adamis Pharmaceuticals?

Adamis Pharmaceuticals saw a increase in short interest in October. As of October 29th, there was short interest totaling 14,160,000 shares, an increase of 47.3% from the October 14th total of 9,610,000 shares. Based on an average daily volume of 6,180,000 shares, the short-interest ratio is currently 2.3 days.
View Adamis Pharmaceuticals' Short Interest.

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, April 21st 2022.
View our earnings forecast for Adamis Pharmaceuticals.

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) posted its quarterly earnings results on Monday, November, 22nd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.06) by $0.03. The specialty pharmaceutical company earned $0.76 million during the quarter. Adamis Pharmaceuticals had a negative trailing twelve-month return on equity of 126.38% and a negative net margin of 458.77%.
View Adamis Pharmaceuticals' earnings history.

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the following people:

• Dennis J. Carlo, President, Chief Executive Officer & Director
• Karen K. Daniels, Vice President-Operations
• David C. Benedicto, Chief Financial & Accounting Officer
• Ronald B. Moss, Chief Medical Officer
• Thomas H. Moll, Vice President-Research

Who are some of Adamis Pharmaceuticals' key competitors?

Some companies that are related to Adamis Pharmaceuticals include Rigel Pharmaceuticals (RIGL), Geron (GERN), Albireo Pharma (ALBO), Evelo Biosciences (EVLO), Provention Bio (PRVB), CytomX Therapeutics (CTMX), Nkarta (NKTX), Rhythm Pharmaceuticals (RYTM), Vaccitech (VACC), Aldeyra Therapeutics (ALDX), Omeros (OMER), Mirum Pharmaceuticals (MIRM), Aadi Bioscience (AADI), Thorne Healthtech (THRN) and Foghorn Therapeutics (FHTX).
View all of ADMP's competitors.

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.90%), Millennium Management LLC (0.37%), Atom Investors LP (0.04%), Citadel Advisors LLC (0.00%), HighTower Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss.
View institutional ownership trends for Adamis Pharmaceuticals.

Which institutional investors are selling Adamis Pharmaceuticals stock?

ADMP stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.
View insider buying and selling activity for Adamis Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Adamis Pharmaceuticals stock?

ADMP stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Atom Investors LP, Geode Capital Management LLC, and HighTower Advisors LLC.
View insider buying and selling activity for Adamis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $0.75.

How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals has a market capitalization of $111.66 million and generates $16.53 million in revenue each year.

How many employees does Adamis Pharmaceuticals have?

Adamis Pharmaceuticals employs 130 workers across the globe.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com.

Where are Adamis Pharmaceuticals' headquarters?

Adamis Pharmaceuticals is headquartered at 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at [email protected].